CF Foundation Awards Leading Research Organization Funding to Screen for Potential B. Cepacia Therapy

The Cystic Fibrosis Foundation awarded nearly $700,000 to Calibr, the drug discovery and development arm of Scripps Research, to screen for a compound that could be used to treat Burkholderia cepacia complex infections. 

| 2 min read

The Cystic Fibrosis Foundation has awarded a $692,000, two-year contract to Calibr, the drug discovery and development arm of Scripps Research, to screen for a compound that could be used to treat infections caused by the 22 bacterial species known as Burkholderia cepacia complex.

B. cepacia complex infections among people with cystic fibrosis are rare -- only 2.6 percent of the U.S. CF population cultured positive in 2018 -- but severe, and there are few treatments available. People with CF who have one particular species of B. cepacia -- B. cenocepacia -- are often rejected as transplant candidates by many lung transplant centers because there is a chance of severe infections after the transplant.

Scientists at Calibr, based in La Jolla, Calif., will screen a library of 13,000 molecules that have been used in developing drugs for other diseases to determine whether any could be used as an antimicrobial to kill B. cepacia. If there are any positive hits, Calibr will explore whether the molecules could be developed into a potential B. cepacia treatment.

Despite the approval of treatments for the underlying cause of CF, many people with CF will continue to need treatments for disease manifestations, such as infections. The CF Foundation has committed at least $100 million from 2019-2023 to the Infection Research Initiative as part of a sweeping effort to address the chronic and intractable infections that are a hallmark of cystic fibrosis.

For more information on this announcement, please see the Calibr release.

Share this article
Drug Pipeline | About the CF Foundation
Recent news
CF Foundation Establishes Health Equity Awards to Advance Research Toward Optimal Health Outcomes
News | 5 min read
CF Foundation Honors the Legacy of Joe O’Donnell
News | 4 min read
CF Foundation Invests up to $5M in Clarametyx Biosciences to Develop a New Anti-Bacterial Therapy 
News | 2 min read
You might also be interested in...
Stay up to date with The Foundation

Sign up for our newsletter to get all of the latest news from The Foundation right in your inbox.